Interpace Biosciences Inc (IDXG)
3.28
+0.29
(+9.70%)
USD |
OTCM |
Nov 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 14.41M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 198.2% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.3457 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.1149 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.12% |
Profile
| Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. |
| URL | https://www.interpace.com |
| Investor Relations URL | http://phx.corporate-ir.net/phoenix.zhtml?c=73639&p=irol-irhome |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 13, 2019 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. |
| URL | https://www.interpace.com |
| Investor Relations URL | http://phx.corporate-ir.net/phoenix.zhtml?c=73639&p=irol-irhome |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Nov. 13, 2019 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |